CDK4/6 inhibitors in luminal breast cancer

Lancet Oncol. 2015 Jan;16(1):2-3. doi: 10.1016/S1470-2045(14)71188-X. Epub 2014 Dec 16.

Authors

Michael Gnant¹, Guenther G Steger², Rupert Bartsch²

Affiliations

¹ Departments of Surgery, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.
² Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.

PMID: 25524801
DOI: 10.1016/S1470-2045(14)71188-X

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / analysis*
Breast Neoplasms / drug therapy*
Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
Female
Humans
Receptor, ErbB-2 / analysis*
Receptors, Estrogen / analysis*

Substances

Biomarkers, Tumor
Receptors, Estrogen
ERBB2 protein, human
Receptor, ErbB-2
CDK4 protein, human
CDK6 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6